ArticleJournal of neuro-oncology2025
Modulating the pace: systemic targeted therapy, brain metastasis velocity, and outcomes after Gamma Knife radiosurgery in breast cancer brain metastases.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeManagement of brain metastases from breast cancer (BMBC) is advancing with stereotactic radiosurgery (SRS) and systemic targeted therapies. However, the role of SRS in cases with a high intracranial lesion burden and the impact of systemic therapy on disease progression remain uncertain.
methodsWe retrospectively analyzed 230 BMBC patients treated with Gamma Knife radiosurgery (GKRS) from 2014 to 2024. Data on lesion count, systemic therapy, and outcomes were collected. Patients were stratified by lesion number (≤ 4 vs. > 4) and brain metastasis velocity (BMV: <4, 4–13, > 13 new lesions/year). Survival and progression were assessed using Kaplan–Meier analysis, chi-square tests, and multivariable regression.
resultsGKRS was effective and safe even for patients with > 4 lesions, showing no significant differences in survival (median OS: 65.0 vs. 63.0 months), retreatment rates, or adverse radiation effects compared to patients with fewer lesions. Similar results were observed for those with more than 10 and 20 lesions. Targeted systemic therapy reduced BMV (7.9 vs. 11.4 lesions/year, p = 0.047) and delayed retreatment but did not improve survival. Molecular subtype was significantly associated with the BMV group but not with BMV as a continuous variable. The observed survival exceeded predictions from older prognostic models. Higher BMV was associated with increased retreatment and shorter survival after GKRS.
conclusionsGKRS is safe and effective for BMBC patients with extensive intracranial disease. Systemic targeted therapies slow intracranial progression and delay retreatment. Subtype-specific metastatic velocity may guide risk-adjusted strategies, supporting a personalized approach that considers lesion burden, molecular subtype, and disease kinetics.
Indexed as
Identifiers
41099786What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.